Status: Recruiting
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)
Participants needed: 5
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Akros Pharma Inc.Updated: Feb 9, 2026Locations: 1
Eligibility criteria
Clinical History: At least 2 typical clinical symptoms (e.g., urticarial skin ra... [+3]
Has chronic infantile neurologic cutaneous articular syndrome (CINCA)/neonatal-o... [+2]